A Dominus and Cheyne Capital partnership wins City of London approval to convert the Grade II-listed Ibex House into a 382-room hotel, slated for a late 2028 opening, complete with a hospitality academy and restored pub.
Amazon's recent workforce reductions, bringing total corporate cuts to 30,000, reflect a broader shift in how layoffs are perceived. No longer framed as a sign of failure, they are increasingly presented as a strategic, forward-looking move to streamline operations and focus on priorities like AI, a narrative that resonates with investors despite the human impact.
The United States' formal exit from the World Health Organization, effective January 2026, may not trigger immediate changes, but experts warn it could gradually reshape the landscape of healthcare expenses for millions of Americans.
Amgen has transferred full rights for the atopic dermatitis drug rocatinlimab back to Kyowa Kirin, clearing the path for the Japanese firm to pursue US approval by 2026. The move comes despite the drug meeting all trial endpoints, reflecting Amgen's portfolio reprioritization and a tempered market outlook for the OX40 inhibitor class.
A 15-day blackout of ESPN networks on YouTube TV last fall carved a $110 million hole in the sports giant's quarterly operating income, new financial disclosures reveal. The dispute underscores the high-stakes brinkmanship now defining relationships between content owners and distribution platforms.
As the housing market evolves, a three-digit number remains the decisive factor for mortgage seekers. The latest FICO scoring model now considers rental history, potentially opening doors for millions of aspiring homeowners.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Analysts at Piper Sandler have increased their price target for Permian Basin-focused producer Diamondback Energy (FANG) to $218, maintaining an Overweight rating. The move comes as the firm anticipates solid Q4 results for gas-focused companies, while oil producers navigate a tougher pricing environment.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
Analyst Joe Laetsch raises HF Sinclair's price target, highlighting favorable crude differentials and a recent $38 million acquisition aimed at expanding its lubricants business, as the refiner lands on a list of top low-risk dividend stocks.
Seaport Research analyst Scott Graham lowered Badger Meter's price target to $220 from $255, citing a slower sales pace in early 2025. The firm maintains a Buy rating, anticipating a stronger second half. The water technology company recently reported record annual sales and profits.
Truist Securities raises its price target on Huntington Bancshares (HBAN) following a robust Q4 performance, as the regional bank forecasts record interest income growth and benefits from improving industry tailwinds.
Insurance brokerage giant Arthur J. Gallagher reported robust fourth-quarter profit growth, driven by resilient demand. However, Truist Securities has lowered its price target on the stock, citing valuation pressures across the property & casualty brokerage sector.
Stifel Nicolaus lowered its price target on Altria Group (MO) by $4 to $68, citing higher-than-expected operating costs. Despite near-term headwinds, the firm reaffirmed its Buy rating, pointing to the tobacco giant's resilient dividend profile and long-term earnings guidance.
Scotiabank has lowered its price target for Comcast (CMCSA), reflecting ongoing pressure in its core broadband business as the media giant reports higher-than-expected customer losses in Q4 and faces fierce competition from fiber and fixed-wireless rivals.
Despite a partial recovery, Pfizer's stock remains significantly below its pandemic-era peak. As 2026 approaches, the pharmaceutical giant confronts a critical juncture defined by looming patent expirations, a high-stakes catch-up effort in the lucrative GLP-1 market, and a dividend under pressure.
Warren Buffett once admitted that managing a smaller pool of capital can be a 'huge structural advantage.' For retail investors, this isn't just theory—it's a practical edge in accessing high-growth opportunities that are now out of reach for the investing giant.
Disney's first fiscal quarter of 2026 saw revenue climb to $25.98 billion, buoyed by record theme park sales and blockbuster films. While streaming income surged dramatically, the company has followed Netflix's lead in ceasing public reporting of Disney+ and Hulu subscriber numbers, shifting investor focus to profitability.
As the U.S. Treasury prepares its quarterly debt issuance update, bond dealers are on high alert for any shift in strategy aimed at managing soaring yields. While major changes are seen as unlikely, the administration's broader financial interventions have markets questioning the long-held "regular and predictable" borrowing mantra.
A provocative analysis suggests the widespread adoption of GLP-1 drugs like Ozempic and Wegovy could trim airline fuel bills by reducing passenger weight, potentially passing savings to travelers. But industry experts debate whether the math adds up.
